Treatments for Translocation RCC Require Novel Therapeutic Targets
Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.
Marconj Dinatale Yasser Mohamed Ali Clinical Cancer Research International Kidney Cancer Symposium Johns Hopkins University World Health Organization
Source: onclive.com